Literature DB >> 3815279

Surgery as part of a combined modality approach for inflammatory breast carcinoma.

P Schäfer, P Alberto, M Forni, D Obradovic, G Pipard, F Krauer.   

Abstract

From November 1977 to February 1984 21 patients with inflammatory breast carcinoma (IBC) were treated in a prospective, nonrandomized study with initial chemotherapy, consisting of a combination of chlorambucil, methotrexate, 5-fluorouracil, and doxorubicin. Modified radical mastectomy was performed after three courses of chemotherapy followed by another six courses of the same chemotherapy. Locoregional radiotherapy concluded the treatment program. All patients responded clinically to the initial chemotherapy. Modified radical mastectomy provided a direct histologic control of the effectiveness of the treatment and, in case of tumor persistence, allowed cytoreduction. No scarring problems were observed and postoperative chemotherapy could be administered without any delay. Radiotherapy was decisive for locoregional tumor control which was obtained in all patients who were treated strictly according to the protocol. Dermal lymphatic involvement represented in this series of clinical inflammatory breast carcinoma no pejorative feature and positive hormone receptors failed to be of predictive value for response to treatment. Considerably variable tumor persistence after initial chemotherapy and the results relative to local tumor control advocate surgery as part of a combined modality approach for inflammatory breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815279     DOI: 10.1002/1097-0142(19870315)59:6<1063::aid-cncr2820590603>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Authors:  E H Koh; A U Buzdar; F C Ames; S E Singletary; M D McNeese; D Frye; F A Holmes; G Fraschini; V Hug; R L Theriault
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.

Authors:  Vinita Takiar; Catherine L Akay; Michael C Stauder; Welela Tereffe; Ricardo H Alvarez; Karen E Hoffman; George H Perkins; Eric A Strom; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward
Journal:  Springerplus       Date:  2014-03-31

3.  The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients.

Authors:  B Chevallier; P Bastit; Y Graic; J F Menard; J P Dauce; J P Julien; B Clavier; A Kunlin; J D'Anjou
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

4.  Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.

Authors:  D Genet; C Lejeune; P Bonnier; Y Aubard; L Venat-Bouvet; D J Adjadj; J Martin; J L Labourey; A Benyoub; P Clavère; V Lebrun-Ly; P Juin; L Piana; N Tubiana-Mathieu
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.